SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies

Neutralization escape by SARS-CoV-2 variants, as has been observed in the 501Y.V2 (B.1.351) variant, has impacted the efficacy of first generation COVID-19 vaccines. Here, the antibody response to the 501Y.V2 variant was examined in a cohort of patients hospitalized with COVID-19 in early 2021 - whe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:bioRxiv
Main Authors: Moyo-Gwete, Thandeka, Madzivhandila, Mashudu, Makhado, Zanele, Ayres, Frances, Mhlanga, Donald, Oosthuysen, Brent, Lambson, Bronwen E., Kgagudi, Prudence, Tegally, Houriiyah, Iranzadeh, Arash, Doolabh, Deelan, Tyers, Lynn, Chinhoyi, Lionel R., Mennen, Mathilda, Skelem, Sango, Marais, Gert, Wibmer, Constantinos Kurt, Bhiman, Jinal N, Ueckermann, Veronica, Rossouw, Theresa, Boswell, Michael, de Oliveira, Tulio, Williamson, Carolyn, Burgers, Wendy A, Ntusi, Ntobeko, Morris, Lynn, Moore, Penny L
Formato: Artigo
Idioma:Inglês
Publicado em: Cold Spring Harbor Laboratory 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7941631/
https://ncbi.nlm.nih.gov/pubmed/33688657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.03.06.434193
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados